Pharmaceutical Technology Europe September October 2025

Success depends on collaboration, resilience, and a focus on improving outcomes for patients worldwide.

The European Union aims to become the most attractive place for life science by 2030.

Novo Nordisk’s Wegovy will be competing with Madrigal Pharmaceuticals’ Rezdiffra in the metabolic dysfunction-associated steatohepatitis arena.